| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.13 | 0.5 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | -0.053 | 0.5 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | phloretin | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | -0.04 | 0.5 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | AMG-706 | FIMM | pan-cancer | AAC | 0.12 | 0.5 |